321 related articles for article (PubMed ID: 33222245)
1. Regulatory challenges with biosimilars: an update from 20 countries.
Kang HN; Thorpe R; Knezevic I; Casas Levano M; Chilufya MB; Chirachanakul P; Chua HM; Dalili D; Foo F; Gao K; Habahbeh S; Hamel H; Kim GH; Perez Rodriguez V; Putri DE; Rodgers J; Savkina M; Semeniuk O; Srivastava S; Tavares Neto J; Wadhwa M; Yamaguchi T
Ann N Y Acad Sci; 2021 May; 1491(1):42-59. PubMed ID: 33222245
[TBL] [Abstract][Full Text] [Related]
2. The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019.
Kang HN; Thorpe R; Knezevic I;
Biologicals; 2020 May; 65():1-9. PubMed ID: 32224101
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars: Implications for health-system pharmacists.
Lucio SD; Stevenson JG; Hoffman JM
Am J Health Syst Pharm; 2013 Nov; 70(22):2004-17. PubMed ID: 24173009
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
5. Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey.
Castañeda-Hernández G; Sandoval H; Coindreau J; Rodriguez-Davison LF; Pineda C
Pharmacoepidemiol Drug Saf; 2019 Aug; 28(8):1035-1044. PubMed ID: 31148288
[TBL] [Abstract][Full Text] [Related]
6. Iraqi regulatory authority current system and experience with biosimilars.
Al-Kinani KK; Ibrahim MJ; Al-Zubaidi RF; Younus MM; Ramadhan SH; Kadhim HJ; Challand R
Regul Toxicol Pharmacol; 2020 Nov; 117():104768. PubMed ID: 32861742
[TBL] [Abstract][Full Text] [Related]
7. Approval Process: An Overview of Biosimilars in the Oncology Setting.
Sowinski-Raff L
Clin J Oncol Nurs; 2018 Oct; 22(5):13-18. PubMed ID: 30239527
[TBL] [Abstract][Full Text] [Related]
8. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
9. Global regulatory standards for the approval of biosimilars.
Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.
de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R
J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
12. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
[TBL] [Abstract][Full Text] [Related]
13. Biosimilar regulation in the EU.
Kurki P; Ekman N
Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
15. Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view.
Pineda C; Caballero-Uribe CV; de Oliveira MG; Lipszyc PS; Lopez JJ; Mataos Moreira MM; Azevedo VF
Clin Rheumatol; 2015 Apr; 34(4):635-40. PubMed ID: 25673060
[TBL] [Abstract][Full Text] [Related]
16. Postmarketing Safety of Biosimilars: Current Status, Challenges, and Opportunities in the Spontaneous Reporting System.
Singh A; Kalaivani M; Srivastava S; Goyal RK; Gupta SK
Ther Innov Regul Sci; 2020 May; 54(3):667-680. PubMed ID: 33301154
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar medical products - licensing, pharmacovigilance and interchangeability.
Grozdanova A; Netkovska KA; Sterjev Z; Naumovska Z; Zarevski R; Dimovski A; Suturkova L
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016; 37(1):27-36. PubMed ID: 27442414
[TBL] [Abstract][Full Text] [Related]
18. The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy.
Kabir ER; Moreino SS; Sharif Siam MK
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31450637
[TBL] [Abstract][Full Text] [Related]
19. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
Jahnz-Rozyk K; Wiesik-Szewczyk E;
Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
[TBL] [Abstract][Full Text] [Related]
20. Pharmacovigilance and biosimilars: considerations, needs and challenges.
Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]